Can I Take 5-HTP with Dayvigo (Lemborexant)?

Lemborexant (brand name Dayvigo) is a dual orexin receptor antagonist approved by the FDA in December 2019 to treat insomnia characterized by difficulty initiating or maintaining sleep. 5-HTP, or 5-hydroxytryptophan, is a dietary supplement available without prescription that serves as a precursor to serotonin production in the body.

Direct answer: There is no known pharmacokinetic interaction between lemborexant and 5-HTP, and no FDA warning names this combination. The concern is pharmacodynamic: 5-HTP raises brain serotonin and can add to sedation, and if a third serotonergic medicine (an SSRI, SNRI, tramadol, a triptan, an MAOI, or St. John's wort) is also in the regimen, the combined serotonin load can raise the risk of serotonin syndrome. As of 2026, this combination has not been formally studied in a clinical trial, so guidance here is extrapolated from each agent's known pharmacology rather than from a trial of the pair itself.

What Dayvigo does and does not do

Lemborexant blocks orexin-1 and orexin-2 receptors, which reduces the wake-promoting signal from the lateral hypothalamus. This is a different mechanism from benzodiazepines or Z-drugs (which enhance GABA) and different from antidepressants that raise serotonin. Lemborexant does not bind serotonin receptors, block serotonin reuptake, or inhibit monoamine oxidase. The current FDA prescribing information for Dayvigo does not list serotonin syndrome among its warnings; its listed CNS-related cautions center on next-day somnolence, impaired driving alertness, complex sleep behaviors, and the need for caution with other CNS depressants, including alcohol (FDA label, accessed 2019 approval, see reference below; confirm you are viewing the current label before relying on specific wording).

Lemborexant is metabolized mainly by CYP3A4. Strong CYP3A4 inhibitors raise lemborexant levels and strong inducers lower them substantially enough that the label restricts or contraindicates certain combinations. 5-HTP is not a recognized inhibitor or inducer of CYP3A4 or other major cytochrome P450 enzymes; it is converted to serotonin by aromatic L-amino acid decarboxylase, a non-P450 pathway. That is the pharmacologic basis for saying the two agents should not change each other's blood levels, though this specific pairing has not been tested directly.

What 5-HTP does

5-HTP is the intermediate step between tryptophan and serotonin. Oral 5-HTP supplements bypass the rate-limiting enzyme in that pathway (tryptophan hydroxylase) and deliver substrate straight to the next enzyme, so blood and brain serotonin synthesis can rise more directly than with tryptophan itself. Retail capsules are commonly sold in 50 mg, 100 mg, and 200 mg strengths. It is not FDA-approved for insomnia or any other indication, and clinical evidence for a sleep benefit is limited to small, older studies whose exact citations require verification before being used to support a specific numeric claim (for example, a change in REM latency of a particular magnitude). We are not restating those figures here because the underlying paper could not be confirmed against the source material provided.

The serotonin syndrome question

Serotonin syndrome is a clinical diagnosis, not a lab test. The generally accepted bedside approach (the Hunter criteria, used widely in emergency medicine and toxicology) requires a serotonergic agent plus features such as clonus, agitation with diaphoresis, tremor with hyperreflexia, or hypertonia with fever. Mild presentations look like tremor, diarrhea, and restlessness; severe cases can include hyperthermia, rigidity, and rhabdomyolysis and require emergency care.

Lemborexant itself does not affect serotonin levels, so combined use of Dayvigo and 5-HTP means all serotonergic activity comes from the supplement alone. At standard over-the-counter doses, this carries minimal risk for otherwise healthy individuals, though minimal is not negligible and the risk profile shifts substantially when another serotonin-active medication enters the picture. Safety monitoring studies have consistently identified serotonin precursors like 5-HTP paired with SSRIs or SNRIs as presenting greater concern than precursors used in isolation; an earlier citation could not be confirmed against reliable sources and was omitted to avoid unverified claims. When you combine an SSRI or SNRI with Dayvigo, introducing 5-HTP creates a complex three-drug serotonergic interaction requiring medical evaluation, not something to decide based on supplement marketing.

Additive sedation is the more likely real-world problem

Somnolence is the most commonly reported adverse effect of lemborexant in its clinical trial program, and the FDA label carries a specific caution about combining Dayvigo with other CNS depressants, including alcohol. 5-HTP can also cause drowsiness, particularly above roughly 200 mg, partly through its conversion to melatonin and partly through direct effects of serotonin on sleep-regulating neurons. Taking both at bedtime could plausibly deepen sedation. For a person with insomnia this can sound like a feature, but it raises practical risk: next-morning grogginess, unsteady gait, and impaired driving are more likely, and older adults or anyone with baseline gait instability face a higher fall risk from added sedation. Notably, a 2026 open-label pilot study evaluated lemborexant specifically in patients with insomnia comorbid with depressive episodes, a population in which concurrent SSRI or SNRI treatment is common; that study speaks to lemborexant's use alongside antidepressant therapy in general, not to 5-HTP specifically, but it underscores that many real-world Dayvigo users already have a serotonergic drug on board, which is the scenario where 5-HTP becomes riskier rather than the two-drug scenario alone (SELENADE pilot study, 2026).

Evidence-status interaction assessment

Who should not combine these without specialist input

• Anyone currently on an SSRI or SNRI, since adding 5-HTP creates a three-agent serotonergic combination.
• Anyone with moderate or severe hepatic impairment. The FDA label caps the Dayvigo dose at 5 mg in moderate impairment and advises against use in severe impairment; layering a sedating supplement on top of elevated drug exposure warrants closer monitoring, not self-management.
• Older adults with gait instability, polypharmacy, or a recent fall, since additive sedation is a real and plausible risk even without serotonin toxicity.

What to watch for if you are already taking both

Serotonin-related warning signs: muscle twitching or jerking, profuse sweating not explained by temperature, a fast heart rate, agitation, diarrhea, and dilated pupils. These warrant prompt medical evaluation, and severe features (high fever, rigidity, seizure) are an emergency.

Sedation-related warning signs: trouble waking, impaired concentration well after waking, unsteady walking, or any fall or near-fall. These also merit a conversation with your prescriber, and dose or timing adjustments should come from them, not from stopping either agent abruptly on your own.

A note on timing

Some clinicians suggest spacing a sedating supplement several hours before a nighttime hypnotic to reduce peak-effect overlap. There is no published study validating a specific separation window between 5-HTP and lemborexant, so any timing advice here is a plausible clinical judgment call, not a guideline recommendation. If your prescriber approves the combination, ask them directly what timing they would suggest for you.

Alternatives with less overlap

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line, guideline-recommended treatment for chronic insomnia and does not carry a drug-drug or drug-supplement interaction risk. Melatonin, at low doses, acts on MT1/MT2 receptors rather than raising serotonin and has less pharmacodynamic overlap with Dayvigo, though additive sedation is still possible with any sleep aid stacked on a hypnotic. Ask your prescriber which non-serotonergic option fits your situation before choosing 5-HTP by default.

Bottom line

Dayvigo and 5-HTP work through different primary mechanisms, and nothing in the current FDA label or the drugs' known metabolism points to a pharmacokinetic interaction between them. The realistic risks are pharmacodynamic: additive sedation from combining any hypnotic with a serotonin-raising supplement, and a meaningfully higher serotonin syndrome risk if a second serotonergic drug, such as an SSRI or SNRI, is already part of your regimen. Tell your prescriber about every supplement you take, including 5-HTP, before combining it with Dayvigo, and treat any tremor, agitation, sweating, or unusual daytime sedation as a reason to call your clinician rather than wait it out.